Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Doherty (Belfast, United Kingdom), L. Roets (Belfast, United Kingdom), R. Delaney (Belfast, United Kingdom), A. Krasnodembskaya (Belfast, United Kingdom), M. Mall (Berlin, Germany), C. Taggart (Belfast, United Kingdom), S. Weldon (Belfast, United Kingdom). Mesenchymal stem cell therapy in a model of chronic inflammatory lung disease. 3855

Member's Comments

No comment yet.

Related content which might interest you: Mesenchymal stem cell therapy reduces inflammation and damage in a model of chronic lung disease Source: ERS Lung Science Conference 2017 Year: 2017 Mesenchymal stem cells and fibrotic lung diseases Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 Mesenchymal stem cell therapy for severe emphysema Source: ERS Lung Science Conference 2021 Year: 2021 Mesenchymal stem cell therapy for severe emphysema Source: Virtual Congress 2021 – Repair and regeneration in chronic lung disease and lung cancer Year: 2021 The therapeutic potential of the mesenchymal stem cell secretome in a mouse model of chronic inflammatory lung disease Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair Year: 2019 Mesenchymal lineage formation in the lung during development and disease Source: International Congress 2017 – Molecular pathways in lung development Year: 2017 Immunotherapeutic strategy with mesenchymal stem cells modulating inflammation in an experimental model of COPD. Source: Virtual Congress 2020 – New insight into the immunology of asthma and COPD Year: 2020 Mesenchymal stem cell based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysacharride in mice Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury Year: 2008 Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury Source: Eur Respir J, 59 (1) 2004216; 10.1183/13993003.04216-2020 Year: 2022 Characterizing lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Modelling human lung development and disease using pluripotent stem cells Source: International Congress 2015 – Regenerative medicine of the lung: opportunities and threats Year: 2015 Effects of autologous mesenchymal stromal cell treatment for severe emphysema on lung tissue: A clinical trial Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease Year: 2015 Mesenchymal stem cells in aging and IPF Source: ERS Research Seminar 2017 – Integrating systems biology approach in idiopathic pulmonary fibrosis research Year: 2016 Fludarabine in paediatric steroid-refractory inflammatory lung injury after stem cell transplantation Source: Eur Respir J 2013; 41: 479-483 Year: 2013 Restrictive chronic lung function decline after haematopoietic stem cell transplantation Source: Eur Respir J 2016; 47: 336-339 Year: 2016 Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury Source: Eur Respir J 2009; 34: 740 Year: 2009 Induced pluripotent stem cells for generating lung airway stem cells and modelling respiratory disease Source: Eur Respir Monogr 2021; 91: 190-204 Year: 2021 Noninfectious infiltrative lung diseases after allogeneic hematopoïetic stem cell transplantation (HSCT) Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Stem cell therapy attenuates airway and lung parenchyma remodeling in a murine model of chronic allergic asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008